Your shopping cart is currently empty

Soticlestat (OV935) is a potent, selective and orally active cholesterol 24-hydroxylase (CYP46A1) inhibitor. It has the potential for epilepsy syndromes research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $60 | In Stock | In Stock | |
| 5 mg | $147 | In Stock | In Stock | |
| 10 mg | $239 | In Stock | In Stock | |
| 25 mg | $478 | In Stock | In Stock | |
| 50 mg | $688 | In Stock | In Stock | |
| 100 mg | $996 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $162 | In Stock | In Stock |
| Description | Soticlestat (OV935) is a potent, selective and orally active cholesterol 24-hydroxylase (CYP46A1) inhibitor. It has the potential for epilepsy syndromes research. |
| In vitro | Soticlestat inhibits the catalytic activity of human cholesterol 24-hydroxylase (CH24H) in a concentration-dependent manner with an IC50?of 4.5 nM |
| In vivo | Soticlestat treatment lowers brain 24S-hydroxycholesterol in a dose-dependent manner and substantially reduceds premature deaths of APP/PS1-Tg mice at a dose lowering brain 24S-hydroxycholesterol by approximately 50%. Soticlestat can suppress potassium-evoked extracellular glutamate elevations in the hippocampus |
| Synonyms | TAK-935, OV935 |
| Molecular Weight | 373.45 |
| Formula | C23H23N3O2 |
| Cas No. | 1429505-03-2 |
| Smiles | OC1(Cc2ccccc2)CCN(CC1)C(=O)c1cccnc1-c1ccncc1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (267.77 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (10.71 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.